[ Home ] [ Controlled Substances ] [ Stimulants ]
NEA
|
Etilamfetamine (Apetinil) is a stimulant drug of amphetamine chemical class. It is an N-substituted amphetamine with an ethyl group on the amphetamine backbone. It was used as an anorectic or appetite suppressant. Etilamfetamine is a psychoactive drug, which can be used as a recreational drug. Etilamfetamine has been abused as a "designer drug" alternative to amphetamine and possibly methamphetamine. It is a dopamine releasing agent.
Etilamfetamine (Apetinil):
https://drugs.ncats.io/drug/022YON1XMX
https://www.caymanchem.com/msdss/11557m.pdf
It was invented in the early 20th century and was subsequently used as an anorectic or appetite suppressant in the 1950s, but was not as commonly used as other amphetamines. was largely discontinued once newer drugs such as phenmetrazine were introduced. It most likely acts primarily as a dopamine releasing agent. Its activity as a norepinephrine or serotonin releasing agent is not known. Ethylamphetamine can be used as a recreational drug and, while its prevalence is less than amphetamine's, it is still encountered as a substance taken for recreational purposes. Ethylamphetamine produces effects similar to amphetamine and methamphetamine, though its potency is less. At equipotent dosage, ethylamphetamine is subjectively less euphorigenic.
State police to participate in NEA drug take-back - The Drug Enforcement Administration (DEA) is sponsoring the 27th nationwide “Prescription Drug Take Back” initiative on Saturday. The “Take Back” initiative seeks to prevent prescription drug abuse ... Wednesday October 23, 2024 - therepublic.com Cydan, a New Orphan Drug Accelerator, Launches with $16 Million Financing from Leading Investors NEA, Pfizer Venture Investments and Alexandria Real Estate Equities - CAMBRIDGE, Mass.-- (BUSINESS WIRE)-- Cydan, LLC, an orphan drug accelerator that identifies and de-risks programs with therapeutic and commercial potential, today announced its launch with $16 million ... NEA pitches in on a $27M gamble on Tracon's mid-stage cancer drug program - New Enterprise Associates has stepped up to back San Diego-based Tracon Pharmaceuticals, joining a syndicate that is betting $27 million on the company's two cancer therapies, including a mid-stage ... NEA, Pfizer build a launch pad for a portfolio of orphan-drug biotechs - David Mott at New Enterprise Associates has spearheaded the development of an orphan drug accelerator that plans to hunt down the best in vivo-stage assets in academia, biopharma and the nonprofits, ... NEA leads $16m investment in orphan drug accelerator - New Enterprise Associates is betting on an accelerator concept to solve the de-risking riddle inherent to orphan drugs — that is, those targeting rare diseases — and identifying promising orphan drug ... NEA's Jim Barrett: Drug innovation should be rewarded - Society needs to “take seriously the rewards for innovators” through the patent system to improve the biotech investing climate, New Enterprise Associates Inc. General Partner James Barrett said ... NEA Venture Partner Scott Gottlieb, M.D., Nominated To Be Commissioner Of U.S. Food And Drug Administration - CHEVY CHASE, Md., March 11, 2017 /PRNewswire/ -- New Enterprise Associates, Inc. (NEA) Venture Partner Scott Gottlieb, M.D., has been nominated by President Donald J. Trump to serve as Commissioner of ... NEA Backs Startup’s Software to Assess Drug Performance - Venture capitalists increasingly are backing startups that blend computer science and biology in a bid to accelerate drug discovery and the development of novel therapies. Aetion Inc., whose software ...
| ||
| Stimulants | Link to this page |